Equities

Shilpa Medicare Ltd

SHILPAMED:NSI

Shilpa Medicare Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)866.65
  • Today's Change16.60 / 1.95%
  • Shares traded224.04k
  • 1 Year change+145.16%
  • Beta0.9436
Data delayed at least 15 minutes, as of Sep 20 2024 11:22 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Shilpa Medicare Ltd grew revenues 9.66% from 10.50bn to 11.52bn while net income improved from a loss of 324.76m to a gain of 318.74m.
Gross margin65.19%
Net profit margin3.79%
Operating margin14.20%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, Shilpa Medicare Ltd increased its cash reserves by 59.53%, or 113.54m. The company earned 1.35bn from its operations for a Cash Flow Margin of 11.75%. In addition the company generated 467.75m cash from financing while 1.67bn was spent on investing.
Cash flow per share17.27
Price/Cash flow per share54.18
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Shilpa Medicare Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 198.15%. Additionally, five year annualized earnings per share growth ranks below the industry average relative to its peers.
Div yield(5 year avg)0.12%
Div growth rate (5 year)--
Payout ratio (TTM)0.00%
EPS growth(5 years)-23.23
EPS (TTM) vs
TTM 1 year ago
234.95
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.